- BMF-500, an investigational third-generation covalent FLT3 inhibitor, has shown preclinically to be possibly the most potent and selective inhibitor of FLT3 studied to date:
- Greater cytotoxicity: In acute myeloid leukemia (AML) cell lines, 3-hour treatment with BMF-500 followed by washout resulted in greater cell kill at 96 hours than continuous exposure to the noncovalent FLT3 inhibitor gilteritinib
- Sustained FLT3 inhibition: BMF-500 induced complete tumor regression of FLT3-ITD in mouse tumor models and maintained its effect without continued exposure
- Highly selective: The kinase panel assay showed potentially best-in-class selectivity over FLT3
- The efficacy profile of the FLT3 mutant demonstrated a significant advantage over existing FLT3 inhibitors
- About a third of patients diagnosed with AML have an FLT3 mutation, which is associated with poor outcomes
- Biomea Fusion remains on track to submit an IND for BMF-500 in the first half of 2023
REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. BMEAa clinical-stage biopharmaceutical company dedicated to the discovery and development of novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that it has received preclinical data from the investigational covalent FLT3- Inhibitor BMF-500 will be presented under the 64thth ASH Annual Meeting to be held December 10-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
Discovered and developed internally at Biomea using the company’s FUSION™ system, BMF-500 was designed to have a therapeutic profile that supports combinations with standard treatments and/or novel targeted agents such as BMF-219, Biomea’s investigational covalent menin inhibitor , allows . The Company is on track to submit a new drug investigation (IND) application for BMF-500 in the first half of 2023 and, subject to successful new drug approval (IND)…
[ad_2]
Source story
